Euglycemic Diabetic Ketoacidosis When Reducing Insulin Dosage in Patients Taking Sodium Glucose Cotransporter 2 Inhibitor.
10.12771/emj.2017.40.1.55
- Author:
Woo Jin YI
1
;
Soo Kyung KIM
;
Sun Ung YOUN
;
Namkyu KANG
;
Myung Won LEE
;
Seok O PARK
Author Information
1. Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. dmbak@sungae.co.kr
- Publication Type:Case Report
- Keywords:
Diabetic ketoacidosis;
Sodium glucose cotransporter 2
- MeSH:
Blood Glucose;
Dehydration;
Diabetic Ketoacidosis*;
Diarrhea;
Glucagon;
Glucose*;
Humans;
Insulin*;
Ketone Bodies;
Ketosis;
Lipolysis;
Liver;
Pancreas;
Sodium*
- From:The Ewha Medical Journal
2017;40(1):55-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sodium glucose cotransporter 2 (SGLT2) inhibitor has been recently reported of diabetic ketoacidosis due to accumulation of ketone bodies in patients with severe dehydration caused from such like diarrhea even though the patient had normal glucose level. This is a case of ketoacidosis in normal glucose level as production of ketone bodies is stimulated in liver with increased secretion of glucagon by stimulation of α cells in pancreas due to increase of lipolysis caused from reducing insulin and by SGLT2 inhibitor among patients who are under concurrent insulin and SGLT2 inhibitor. Thus, insulin dosage reduction requires caution in order to control blood glucose level on combined treatment of SGLT2 inhibitor in a patient who is administering insulin because the patient may be caused ketoacidosis in normal blood glucose level.
